Raltegravir pharmacokinetics during pregnancy.

ABSTRACT:

Objective

We evaluated the pharmacokinetics (PK) of raltegravir in HIV-infected women during pregnancy and postpartum.

Methods

International Maternal Pediatric Adolescent AIDS Clinical Trials 1026s is an ongoing prospective study of antiretroviral PK during pregnancy (NCT00042289). Women receiving 400 mg raltegravir twice daily in combination antiretroviral therapy had intensive steady-state 12-hour PK profiles performed during pregnancy and at 6- to 12-week postpartum. Targets were trough concentration above 0.035 μg/mL, the estimated 10th percentile in nonpregnant historical controls.

Results

Median raltegravir area under the curve was 6.6 μg·h/mL for second trimester (n = 16), 5.4 μg·h/mL for third trimester (n = 41), and 11.6 μg·h/mL postpartum (n = 38) (P = 0.03

SUBMITTER: Watts DH 

PROVIDER: S-EPMC4213295 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature